vs

Side-by-side financial comparison of Velocity Financial, Inc. (VEL) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Velocity Financial, Inc. is the larger business by last-quarter revenue ($51.6M vs $27.6M, roughly 1.9× Zymeworks Inc.). Velocity Financial, Inc. runs the higher net margin — 67.3% vs -71.0%, a 138.3% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 32.8%). Velocity Financial, Inc. produced more free cash flow last quarter ($17.9M vs $-31.8M).

Velocity Financial, Inc. is a U.S.-headquartered real estate finance company that offers specialized mortgage loan solutions primarily for residential investment properties. It partners with independent mortgage brokers nationwide, providing real estate investors with short-term bridge loans and long-term rental property financing options tailored to their operational needs.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

VEL vs ZYME — Head-to-Head

Bigger by revenue
VEL
VEL
1.9× larger
VEL
$51.6M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+39.8% gap
ZYME
72.6%
32.8%
VEL
Higher net margin
VEL
VEL
138.3% more per $
VEL
67.3%
-71.0%
ZYME
More free cash flow
VEL
VEL
$49.7M more FCF
VEL
$17.9M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
VEL
VEL
ZYME
ZYME
Revenue
$51.6M
$27.6M
Net Profit
$34.8M
$-19.6M
Gross Margin
Operating Margin
97.0%
-80.1%
Net Margin
67.3%
-71.0%
Revenue YoY
32.8%
72.6%
Net Profit YoY
67.0%
34.3%
EPS (diluted)
$0.90
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VEL
VEL
ZYME
ZYME
Q4 25
$51.6M
Q3 25
$49.1M
$27.6M
Q2 25
$47.6M
$48.7M
Q1 25
$37.5M
$27.1M
Q4 24
$38.9M
$31.0M
Q3 24
$35.1M
$16.0M
Q2 24
$32.4M
$19.2M
Q1 24
$29.5M
$10.0M
Net Profit
VEL
VEL
ZYME
ZYME
Q4 25
$34.8M
Q3 25
$25.4M
$-19.6M
Q2 25
$26.0M
$2.3M
Q1 25
$18.9M
$-22.6M
Q4 24
$20.8M
$-23.5M
Q3 24
$15.8M
$-29.9M
Q2 24
$14.8M
$-37.7M
Q1 24
$17.3M
$-31.7M
Operating Margin
VEL
VEL
ZYME
ZYME
Q4 25
97.0%
Q3 25
72.1%
-80.1%
Q2 25
71.3%
-1.4%
Q1 25
71.7%
-94.5%
Q4 24
82.5%
-71.6%
Q3 24
60.6%
-213.8%
Q2 24
61.3%
-222.9%
Q1 24
78.8%
-376.9%
Net Margin
VEL
VEL
ZYME
ZYME
Q4 25
67.3%
Q3 25
51.7%
-71.0%
Q2 25
54.6%
4.8%
Q1 25
50.4%
-83.5%
Q4 24
53.5%
-75.8%
Q3 24
45.1%
-186.6%
Q2 24
45.6%
-195.8%
Q1 24
58.5%
-315.6%
EPS (diluted)
VEL
VEL
ZYME
ZYME
Q4 25
$0.90
Q3 25
$0.65
$-0.26
Q2 25
$0.69
$0.03
Q1 25
$0.51
$-0.30
Q4 24
$0.56
$-0.32
Q3 24
$0.44
$-0.39
Q2 24
$0.42
$-0.49
Q1 24
$0.49
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VEL
VEL
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$92.1M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$672.5M
$320.1M
Total Assets
$7.4B
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VEL
VEL
ZYME
ZYME
Q4 25
$92.1M
Q3 25
$99.0M
$64.8M
Q2 25
$79.6M
$98.3M
Q1 25
$51.7M
$76.2M
Q4 24
$49.9M
$66.1M
Q3 24
$44.1M
$122.4M
Q2 24
$47.4M
$71.0M
Q1 24
$34.8M
$114.8M
Stockholders' Equity
VEL
VEL
ZYME
ZYME
Q4 25
$672.5M
Q3 25
$634.3M
$320.1M
Q2 25
$597.9M
$334.5M
Q1 25
$563.2M
$325.0M
Q4 24
$516.9M
$338.8M
Q3 24
$484.6M
$367.0M
Q2 24
$471.3M
$406.2M
Q1 24
$452.9M
$438.0M
Total Assets
VEL
VEL
ZYME
ZYME
Q4 25
$7.4B
Q3 25
$7.0B
$397.3M
Q2 25
$6.5B
$408.4M
Q1 25
$6.0B
$425.5M
Q4 24
$5.5B
$463.1M
Q3 24
$5.2B
$487.2M
Q2 24
$4.9B
$515.6M
Q1 24
$4.6B
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VEL
VEL
ZYME
ZYME
Operating Cash FlowLast quarter
$18.2M
$-31.4M
Free Cash FlowOCF − Capex
$17.9M
$-31.8M
FCF MarginFCF / Revenue
34.6%
-115.2%
Capex IntensityCapex / Revenue
0.5%
1.5%
Cash ConversionOCF / Net Profit
0.52×
TTM Free Cash FlowTrailing 4 quarters
$40.3M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VEL
VEL
ZYME
ZYME
Q4 25
$18.2M
Q3 25
$11.5M
$-31.4M
Q2 25
$7.7M
$12.1M
Q1 25
$3.5M
$-3.4M
Q4 24
$37.8M
$-41.5M
Q3 24
$-17.6M
$-5.9M
Q2 24
$11.5M
$-25.0M
Q1 24
$10.6M
$-37.7M
Free Cash Flow
VEL
VEL
ZYME
ZYME
Q4 25
$17.9M
Q3 25
$11.4M
$-31.8M
Q2 25
$7.6M
$11.6M
Q1 25
$3.5M
$-3.4M
Q4 24
$37.5M
$-41.8M
Q3 24
$-17.6M
$-6.8M
Q2 24
$11.4M
$-25.6M
Q1 24
$10.5M
$-37.9M
FCF Margin
VEL
VEL
ZYME
ZYME
Q4 25
34.6%
Q3 25
23.2%
-115.2%
Q2 25
15.9%
23.7%
Q1 25
9.2%
-12.6%
Q4 24
96.4%
-134.8%
Q3 24
-50.3%
-42.4%
Q2 24
35.1%
-133.0%
Q1 24
35.8%
-377.5%
Capex Intensity
VEL
VEL
ZYME
ZYME
Q4 25
0.5%
Q3 25
0.1%
1.5%
Q2 25
0.2%
1.1%
Q1 25
0.2%
0.1%
Q4 24
0.7%
1.0%
Q3 24
0.2%
5.6%
Q2 24
0.3%
3.1%
Q1 24
0.1%
1.8%
Cash Conversion
VEL
VEL
ZYME
ZYME
Q4 25
0.52×
Q3 25
0.45×
Q2 25
0.29×
5.21×
Q1 25
0.19×
Q4 24
1.81×
Q3 24
-1.11×
Q2 24
0.78×
Q1 24
0.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VEL
VEL

Related Party$19.3M37%
Nonrelated Party$16.9M33%
Other$15.4M30%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons